<p>Johnson &amp; Johnson announced that 11 abstracts featuring new data from its neuropsychiatry portfolio and pipeline will be presented at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), scheduled for January 12-15, 2026, in Nassau, Bahamas. The presentations will cover clinical research on major depressive disorder (MDD) and treatment-resistant depression (TRD), including Phase 3 analyses of CAPLYTA® (lumateperone) for adjunctive major depressive disorder, post-hoc analyses of SPRAVATO® (esketamine) on anhedonia in TRD, and comparative tolerability data for adjunctive seltorexant versus adjunctive quetiapine XR in MDD with insomnia symptoms. Additional preclinical and translational research on novel mechanisms and AI-driven precision medicine tools will also be presented at the meeting. Results from these studies will be shared during poster sessions on January 14 and 15, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson &amp; Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: CG61655) on January 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

Johnson & Johnson Unveils New Phase 3 Data on Depression Treatments at ACNP Meeting